Great expectations to control the pandemic are placed in vaccines against COVID-19.Currently, the four COVID-19 vaccines approved in the European Union. We have designedthe study assessing the anti-SARS-CoV-2 IgG antibody titer after vaccination cycle theBNT162b2 vaccine in several time points relating these results to the COVID-19 historyand severity of symptoms during the disease and after the first and second vaccine dose
The study includes healthy, unselected volunteers from the staff of Antoni Jurasz
University Hospital No.1 in Bydgoszcz and students of Collegium Medicum, Nicolaus
Copernicus University. To meet the inclusion criteria patients will have to be vaccinated
with two doses of the BNT162b2 vaccine. The assessment of the anti-SARS-CoV-2 IgG
antibody titer at several time points in each participant. Fresh serum samples were used
to measure SARS-CoV-2 IgG on the Siemens Atellica system (Siemens Healthineers, Erlangen,
Germany). Results of SARS-CoV-2 IgG were given as U/ml, whereby the cut-off for
positivity was defined as ≥1.0 U/ml.
Diagnostic Test: assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination
schedule willing to receive a 3rd dose of vaccine
Diagnostic Test: assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
evaluation of anti-SARS-CoV-2 IgG antibodies in patients after 2-dose vaccination
schedule unwilling to receive a 3rd dose of vaccine
Inclusion Criteria:
- Provision of informed consent to study
- Age ≥ 18 years
- Receiving two doses of the BNT162b2 vaccine
Exclusion Criteria:
- patients who did not complete 2-dose vaccination schedule
- patients who received any other vaccine than BNT162b2
- patients considered by investigator to be unable to cooperate
Cardiology Department, Dr. A. Jurasz University Hospital
Bydgoszcz, Kujawsko-Pomorskie, Poland
Jacek Kubica, Prof., Principal Investigator
Collegium Medicum w Bydgoszczy